Mr. Ringo became a director in July 2014, following the Assembly Pharmaceuticals acquisition, and was named non-executive Chairman in 2015. Mr. Ringo served as Interim Chief Executive Officer of Five Prime Therapeutics from September 2019 until April 2020. From 2010 until 2015, Mr. Ringo served as a Senior Advisor at Barclays Capital, the global investment banking division of Barclays Bank PLC, and also as Strategic Advisor at Sofinnova Ventures, a life sciences-focused investment firm. From April 2008 until his retirement in April 2010, Mr. Ringo served as Senior Vice President of Strategy and Business Development for Pfizer and was responsible for guiding Pfizer’s overall strategic planning and business development activities. Prior to joining Pfizer, Mr. Ringo was President and Chief Executive Officer of Abgenix, a public biotechnology company later acquired by Amgen. His experience in the global pharmaceutical sector also includes nearly 30 years with Eli Lilly and Co., where he held a number of executive roles and was a member of Lilly's operating committee. Mr. Ringo currently serves as a director of Sensei Biotherapeutics, a public biotechnology company. He previously served as chairman of Five Prime Therapeutics and as a director of Immune Design, Sangamo Biosciences, Mirati Technologies, Onyx Pharmaceuticals and Dermira, each of which was a public company during Mr. Ringo’s service as a director. Mr. Ringo received a BS in Business Administration and an MBA from the University of Dayton.